Hani N Sabbah1, Ramesh C Gupta2, Smita Kohli2, Mengjun Wang2, Souheila Hachem2, Kefei Zhang2. 1. From the Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI. hsabbah1@hfhs.org. 2. From the Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI.
Abstract
BACKGROUND: Elamipretide (MTP-131), a novel mitochondria-targeting peptide, was shown to reduce infarct size in animals with myocardial infarction and improve renal function in pigs with acute and chronic kidney injury. This study examined the effects of chronic therapy with elamipretide on left ventricular (LV) and mitochondrial function in dogs with heart failure (HF). METHODS AND RESULTS: Fourteen dogs with microembolization-induced HF were randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5 mg/kg once daily, HF+ELA, n=7) or saline (control, HF-CON, n=7). LV ejection fraction, plasma n-terminal pro-brain natriuretic peptide, tumor necrosis factor-α, and C-reactive protein were measured before (pretreatment) and 3 months after initiating therapy (post-treatment). Mitochondrial respiration, membrane potential (Δψm), maximum rate of ATP synthesis, and ATP/ADP ratio were measured in isolated LV cardiomyocytes obtained at post-treatment. In HF-CON dogs, ejection fraction decreased at post-treatment compared with pretreatment (29 ± 1% versus 31 ± 2%), whereas in HF+ELA dogs, ejection fraction significantly increased at post-treatment compared with pretreatment (36 ± 2% versus 30 ± 2%; P<0.05). In HF-CON, n-terminal pro-brain natriuretic peptide increased by 88 ± 120 pg/mL during follow-up but decreased significantly by 774 ± 85 pg/mL in HF+ELA dogs (P<0.001). Treatment with elamipretide also normalized plasma tumor necrosis factor-α and C-reactive protein and restored mitochondrial state-3 respiration, Δψm, rate of ATP synthesis, and ATP/ADP ratio (ATP/ADP: 0.38 ± 0.04 HF-CON versus 1.16 ± 0.15 HF+ELA; P<0.001). CONCLUSIONS: Long-term therapy with elamipretide improves LV systolic function, normalizes plasma biomarkers, and reverses mitochondrial abnormalities in LV myocardium of dogs with advanced HF. The results support the development of elamipretide for the treatment of HF.
BACKGROUND:Elamipretide (MTP-131), a novel mitochondria-targeting peptide, was shown to reduce infarct size in animals with myocardial infarction and improve renal function in pigs with acute and chronic kidney injury. This study examined the effects of chronic therapy with elamipretide on left ventricular (LV) and mitochondrial function in dogs with heart failure (HF). METHODS AND RESULTS: Fourteen dogs with microembolization-induced HF were randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5 mg/kg once daily, HF+ELA, n=7) or saline (control, HF-CON, n=7). LV ejection fraction, plasma n-terminal pro-brain natriuretic peptide, tumor necrosis factor-α, and C-reactive protein were measured before (pretreatment) and 3 months after initiating therapy (post-treatment). Mitochondrial respiration, membrane potential (Δψm), maximum rate of ATP synthesis, and ATP/ADP ratio were measured in isolated LV cardiomyocytes obtained at post-treatment. In HF-CON dogs, ejection fraction decreased at post-treatment compared with pretreatment (29 ± 1% versus 31 ± 2%), whereas in HF+ELAdogs, ejection fraction significantly increased at post-treatment compared with pretreatment (36 ± 2% versus 30 ± 2%; P<0.05). In HF-CON, n-terminal pro-brain natriuretic peptide increased by 88 ± 120 pg/mL during follow-up but decreased significantly by 774 ± 85 pg/mL in HF+ELAdogs (P<0.001). Treatment with elamipretide also normalized plasma tumor necrosis factor-α and C-reactive protein and restored mitochondrial state-3 respiration, Δψm, rate of ATP synthesis, and ATP/ADP ratio (ATP/ADP: 0.38 ± 0.04 HF-CON versus 1.16 ± 0.15 HF+ELA; P<0.001). CONCLUSIONS: Long-term therapy with elamipretide improves LV systolic function, normalizes plasma biomarkers, and reverses mitochondrial abnormalities in LV myocardium of dogs with advanced HF. The results support the development of elamipretide for the treatment of HF.
Authors: Luis Alberto Luévano-Martínez; Maria Fernanda Forni; Valquiria Tiago dos Santos; Nadja C Souza-Pinto; Alicia J Kowaltowski Journal: Biochim Biophys Acta Date: 2015-04-02
Authors: Alfonso Eirin; Zilun Li; Xin Zhang; James D Krier; John R Woollard; Xiang-Yang Zhu; Hui Tang; Sandra M Herrmann; Amir Lerman; Stephen C Textor; Lilach O Lerman Journal: Hypertension Date: 2012-10-08 Impact factor: 10.190
Authors: Alexander V Birk; Shaoyi Liu; Yi Soong; William Mills; Pradeep Singh; J David Warren; Surya V Seshan; Joel D Pardee; Hazel H Szeto Journal: J Am Soc Nephrol Date: 2013-07-11 Impact factor: 10.121
Authors: Dae Yun Seo; Hyo-Bum Kwak; Amy Hyein Kim; Se Hwan Park; Jun Won Heo; Hyoung Kyu Kim; Jeong Rim Ko; Sam Jun Lee; Hyun Seok Bang; Jun Woo Sim; Min Kim; Jin Han Journal: Pflugers Arch Date: 2019-04-23 Impact factor: 3.657
Authors: Mariya T Sweetwyne; Jeffrey W Pippin; Diana G Eng; Kelly L Hudkins; Ying Ann Chiao; Matthew D Campbell; David J Marcinek; Charles E Alpers; Hazel H Szeto; Peter S Rabinovitch; Stuart J Shankland Journal: Kidney Int Date: 2017-01-04 Impact factor: 10.612
Authors: Brian C Tse; Galina Dvoriantchikova; Wensi Tao; Ryan A Gallo; John Y Lee; Dmitry Ivanov; David T Tse; Daniel Pelaez Journal: Exp Eye Res Date: 2020-08-03 Impact factor: 3.467